Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Clinical implementation of the Humacyte human acellular vessel: implications for military and civilian trauma care.

Morrison JJ, McMahon J, DuBose JJ, Scalea TM, Lawson JH, Rasmussen TE.

J Trauma Acute Care Surg. 2019 Apr 25. doi: 10.1097/TA.0000000000002350. [Epub ahead of print]

PMID:
31045737
2.

Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation.

Kirkton RD, Santiago-Maysonet M, Lawson JH, Tente WE, Dahl SLM, Niklason LE, Prichard HL.

Sci Transl Med. 2019 Mar 27;11(485). pii: eaau6934. doi: 10.1126/scitranslmed.aau6934.

PMID:
30918113
3.

Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014.

Bylsma LC, Reichert H, Gage SM, Roy-Chaudhury P, Nordyke RJ, Fryzek J, Dahl SLM, Lithgow T, Lawson JH.

Am J Nephrol. 2019;49(2):156-164. doi: 10.1159/000495355. Epub 2019 Jan 24.

PMID:
30677763
4.

Society of Interventional Radiology Reporting Standards for Thoracic Central Vein Obstruction: Endorsed by the American Society of Diagnostic and Interventional Nephrology (ASDIN), British Society of Interventional Radiology (BSIR), Canadian Interventional Radiology Association (CIRA), Heart Rhythm Society (HRS), Indian Society of Vascular and Interventional Radiology (ISVIR), Vascular Access Society of the Americas (VASA), and Vascular Access Society of Britain and Ireland (VASBI).

Dolmatch BL, Gurley JC, Baskin KM, Nikolic B, Lawson JH, Shenoy S, Saad TF, Davidson I, Baerlocher MO, Cohen EI, Dariushnia SR, Faintuch S, d'Othee BJ, Kinney TB, Midia M, Clifton J; Central Vein Work Group and the Technology Assessment Committee.

J Vasc Access. 2019 Mar;20(2):114-122. doi: 10.1177/1129729818791409. Epub 2018 Aug 13. Review. No abstract available.

PMID:
30101672
5.

Society of Interventional Radiology Reporting Standards for Thoracic Central Vein Obstruction: Endorsed by the American Society of Diagnostic and Interventional Nephrology (ASDIN), British Society of Interventional Radiology (BSIR), Canadian Interventional Radiology Association (CIRA), Heart Rhythm Society (HRS), Indian Society of Vascular and Interventional Radiology (ISVIR), Vascular Access Society of the Americas (VASA), and Vascular Access Society of Britain and Ireland (VASBI).

Dolmatch BL, Gurley JC, Baskin KM, Nikolic B, Lawson JH, Shenoy S, Saad TF, Davidson I, Baerlocher MO, Cohen EI, Dariushnia SR, Faintuch S, Janne d'Othee B, Kinney TB, Midia M, Clifton J; Central Vein Work Group; Technology Assessment Committee.

J Vasc Interv Radiol. 2018 Apr;29(4):454-460.e3. doi: 10.1016/j.jvir.2017.12.013. Epub 2018 Mar 2. No abstract available.

PMID:
29503236
6.

Susceptibility of ePTFE vascular grafts and bioengineered human acellular vessels to infection.

Kirkton RD, Prichard HL, Santiago-Maysonet M, Niklason LE, Lawson JH, Dahl SLM.

J Surg Res. 2018 Jan;221:143-151. doi: 10.1016/j.jss.2017.08.035. Epub 2017 Sep 19.

7.

Interleukin-9 mediates chronic kidney disease-dependent vein graft disease: a role for mast cells.

Zhang L, Wu JH, Otto JC, Gurley SB, Hauser ER, Shenoy SK, Nagi K, Brian L, Wertman V, Mattocks N, Lawson JH, Freedman NJ.

Cardiovasc Res. 2017 Nov 1;113(13):1551-1559. doi: 10.1093/cvr/cvx177.

8.

Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes.

Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH.

Eur J Vasc Endovasc Surg. 2017 Oct;54(4):513-522. doi: 10.1016/j.ejvs.2017.06.024. Epub 2017 Aug 23. Review.

9.

Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.

Beathard GA, Lok CE, Glickman MH, Al-Jaishi AA, Bednarski D, Cull DL, Lawson JH, Lee TC, Niyyar VD, Syracuse D, Trerotola SO, Roy-Chaudhury P, Shenoy S, Underwood M, Wasse H, Woo K, Yuo TH, Huber TS.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):501-512. doi: 10.2215/CJN.11531116. Epub 2017 Jul 20.

10.

Forearm versus upper arm grafts for vascular access.

Gage SM, Lawson JH.

J Vasc Access. 2017 Mar 6;18(Suppl. 1):77-81. doi: 10.5301/jva.5000688. Epub 2017 Mar 5. Review.

PMID:
28297065
11.

Bioengineered hemodialysis access grafts.

Gage SM, Lawson JH.

J Vasc Access. 2017 Mar 6;18(Suppl. 1):56-63. doi: 10.5301/jva.5000692. Epub 2017 Mar 5. Review.

PMID:
28297061
12.

Establishing patient-specific criteria for selecting the optimal upper extremity vascular access procedure.

Woo K, Ulloa J, Allon M, Carsten CG 3rd, Chemla ES, Henry ML, Huber TS, Lawson JH, Lok CE, Peden EK, Scher L, Sidawy A, Maggard-Gibbons M, Cull D.

J Vasc Surg. 2017 Apr;65(4):1089-1103.e1. doi: 10.1016/j.jvs.2016.10.099. Epub 2017 Feb 17. Review.

13.

Operative and perioperative management of infected arteriovenous grafts.

Benrashid E, Youngwirth LM, Mureebe L, Lawson JH.

J Vasc Access. 2017 Jan 18;18(1):13-21. doi: 10.5301/jva.5000613. Epub 2016 Nov 3. Review.

PMID:
27834454
14.

The impact of femoral arterial thrombosis in paediatric cardiac catheterisation: a national study.

Kim J, Sun Z, Benrashid E, Southerland KW, Lawson JH, Fleming GA, Hill KD, Tracy ET.

Cardiol Young. 2017 Jul;27(5):912-917. doi: 10.1017/S104795111600161X. Epub 2016 Nov 8.

PMID:
27821192
15.

Early infection risk with primary versus staged Hemodialysis Reliable Outflow (HeRO) graft implantation.

Griffin AS, Gage SM, Lawson JH, Kim CY.

J Vasc Surg. 2017 Jan;65(1):136-141. doi: 10.1016/j.jvs.2016.07.114. Epub 2016 Sep 26.

16.

Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.

Lawson JH, Glickman MH, Ilzecki M, Jakimowicz T, Jaroszynski A, Peden EK, Pilgrim AJ, Prichard HL, Guziewicz M, Przywara S, Szmidt J, Turek J, Witkiewicz W, Zapotoczny N, Zubilewicz T, Niklason LE.

Lancet. 2016 May 14;387(10032):2026-34. doi: 10.1016/S0140-6736(16)00557-2.

17.

Tissue engineered vascular grafts: Origins, development, and current strategies for clinical application.

Benrashid E, McCoy CC, Youngwirth LM, Kim J, Manson RJ, Otto JC, Lawson JH.

Methods. 2016 Apr 15;99:13-9. doi: 10.1016/j.ymeth.2015.07.014. Epub 2015 Jul 26. Review.

PMID:
26216054
18.

The Preservation and Handling of Vein Grafts in Current Surgical Practice: Findings of a Survey Among Cardiovascular Surgeons of Top-Ranked US Hospitals.

Williams JB, Harskamp RE, Bose S, Lawson JH, Alexander JH, Smith PK, Lopes RD.

JAMA Surg. 2015 Jul;150(7):681-3. doi: 10.1001/jamasurg.2015.0404. No abstract available.

PMID:
25970819
19.

Hemodialysis Reliable Outflow device impingement in the subclavian position: a case report.

Yerxa J, Gage SM, Lawson JH.

J Vasc Access. 2015 Sep-Oct;16(5):428-30. doi: 10.5301/jva.5000380. Epub 2015 Mar 18.

PMID:
25791275
20.

Management of anticoagulation agents in trauma patients.

McCoy CC, Lawson JH, Shapiro ML.

Clin Lab Med. 2014 Sep;34(3):563-74. doi: 10.1016/j.cll.2014.06.013. Epub 2014 Jul 19. Review.

PMID:
25168942
21.

A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients.

Nassar GM, Glickman MH, McLafferty RB, Croston JK, Zarge JI, Katzman HE, Peden EK, Lawson JH, Martinez JM, Thackeray L.

Semin Dial. 2014 May-Jun;27(3):310-8. doi: 10.1111/sdi.12173. Epub 2014 Jan 15.

PMID:
24428351
22.

Preserving David C Sabiston Jr's legacy in medical students' surgical education.

Ali AM, Lawson JH.

J Am Coll Surg. 2013 Dec;217(6):1140-4. doi: 10.1016/j.jamcollsurg.2013.07.401. No abstract available.

PMID:
24246625
23.
24.

Percutaneous interventions on the hemodialysis reliable outflow vascular access device.

Gebhard TA, Bryant JA, Adam Grezaffi J, Pabon-Ramos WM, Gage SM, Miller MJ, Husum KW, Suhocki PV, Sopko DR, Lawson JH, Smith TP, Kim CY.

J Vasc Interv Radiol. 2013 Apr;24(4):543-9. doi: 10.1016/j.jvir.2012.12.027. Epub 2013 Feb 23.

PMID:
23462067
25.

Tissue-engineered vascular grafts: autologous off-the-shelf vascular access?

Manson RJ, Unger JM, Ali A, Gage SM, Lawson JH.

Semin Nephrol. 2012 Nov;32(6):582-91. doi: 10.1016/j.semnephrol.2012.10.010. Review.

PMID:
23217339
26.

A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation.

Peden EK, Leeser DB, Dixon BS, El-Khatib MT, Roy-Chaudhury P, Lawson JH, Menard MT, Dember LM, Glickman MH, Gustafson PN, Blair AT, Magill M, Franano FN, Burke SK.

J Vasc Access. 2013 Apr-Jun;14(2):143-51. doi: 10.5301/jva.5000125. Epub 2012 Nov 20.

27.

Paradoxical embolus following percutaneous thrombectomy of hemodialysis reliable outflow graft.

Gilmore B, Benrashid E, Youngwirth LM, Lawson JH.

J Vasc Access. 2015 Nov-Dec;16(6):533-6. doi: 10.5301/jva.5000485.

PMID:
26515536
28.

Assessment of vascular contrast and depiction of stenoses in abdominopelvic and lower extremity vasculature: comparison of dual-energy MDCT with digital subtraction angiography.

Huang SY, Nelson RC, Miller MJ, Kim CY, Lawson JH, Husarik DB, Boll DT.

Acad Radiol. 2012 Sep;19(9):1149-57. doi: 10.1016/j.acra.2012.04.014. Epub 2012 Jun 27.

PMID:
22743115
29.

Multi-center experience of 164 consecutive Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment.

Gage SM, Katzman HE, Ross JR, Hohmann SE, Sharpe CA, Butterly DW, Lawson JH.

Eur J Vasc Endovasc Surg. 2012 Jul;44(1):93-9. doi: 10.1016/j.ejvs.2012.04.011. Epub 2012 May 12.

30.

Analysis of infection risk following covered stent exclusion of pseudoaneurysms in prosthetic arteriovenous hemodialysis access grafts.

Kim CY, Guevara CJ, Engstrom BI, Gage SM, O'Brien PJ, Miller MJ, Suhocki PV, Lawson JH, Smith TP.

J Vasc Interv Radiol. 2012 Jan;23(1):69-74. doi: 10.1016/j.jvir.2011.09.003. Epub 2011 Oct 22.

PMID:
22019181
31.

Use of autologous blood-derived endothelial progenitor cells at point-of-care to protect against implant thrombosis in a large animal model.

Jantzen AE, Lane WO, Gage SM, Jamiolkowski RM, Haseltine JM, Galinat LJ, Lin FH, Lawson JH, Truskey GA, Achneck HE.

Biomaterials. 2011 Nov;32(33):8356-63. doi: 10.1016/j.biomaterials.2011.07.066. Epub 2011 Aug 15.

32.

Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling.

Conte MS, Nugent HM, Gaccione P, Roy-Chaudhury P, Lawson JH.

J Vasc Surg. 2011 Nov;54(5):1383-9. doi: 10.1016/j.jvs.2011.05.005. Epub 2011 Aug 15.

33.

An early study on the mechanisms that allow tissue-engineered vascular grafts to resist intimal hyperplasia.

Prichard HL, Manson RJ, DiBernardo L, Niklason LE, Lawson JH, Dahl SL.

J Cardiovasc Transl Res. 2011 Oct;4(5):674-82. doi: 10.1007/s12265-011-9306-y. Epub 2011 Jul 12.

34.

Decellularized tissue-engineered blood vessel as an arterial conduit.

Quint C, Kondo Y, Manson RJ, Lawson JH, Dardik A, Niklason LE.

Proc Natl Acad Sci U S A. 2011 May 31;108(22):9214-9. doi: 10.1073/pnas.1019506108. Epub 2011 May 12.

35.

Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia.

Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, Hutchins GD, March KL.

J Vasc Surg. 2011 Jun;53(6):1565-74.e1. doi: 10.1016/j.jvs.2011.01.074. Epub 2011 Apr 22.

36.

In vitro functional testing of endothelial progenitor cells that overexpress thrombomodulin.

Stroncek JD, Xue Y, Haque N, Lawson JH, Reichert WM.

Tissue Eng Part A. 2011 Aug;17(15-16):2091-100. doi: 10.1089/ten.TEA.2010.0631. Epub 2011 May 25.

37.

Use of aspirin associates with longer primary patency of hemodialysis grafts.

Dixon BS, Beck GJ, Dember LM, Vazquez MA, Greenberg A, Delmez JA, Allon M, Himmelfarb J, Hu B, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Lawson JH, Cotton JR Jr, Kusek JW, Feldman HI; Dialysis Access Consortium (DAC) Study Group.

J Am Soc Nephrol. 2011 Apr;22(4):773-81. doi: 10.1681/ASN.2010060582. Epub 2011 Mar 17.

38.

Readily available tissue-engineered vascular grafts.

Dahl SL, Kypson AP, Lawson JH, Blum JL, Strader JT, Li Y, Manson RJ, Tente WE, DiBernardo L, Hensley MT, Carter R, Williams TP, Prichard HL, Dey MS, Begelman KG, Niklason LE.

Sci Transl Med. 2011 Feb 2;3(68):68ra9. doi: 10.1126/scitranslmed.3001426.

39.

Salvaging vascular access and treatment of severe limb edema: case reports on the novel use of the hemodialysis reliable outflow vascular access device.

Gage SM, Ahluwalia HS, Lawson JH.

Ann Vasc Surg. 2011 Apr;25(3):387.e1-5. doi: 10.1016/j.avsg.2010.09.020. Epub 2011 Jan 26.

PMID:
21273039
40.

Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface.

Achneck HE, Sileshi B, Parikh A, Milano CA, Welsby IJ, Lawson JH.

Circulation. 2010 Nov 16;122(20):2068-77. doi: 10.1161/CIRCULATIONAHA.110.936773. Review. No abstract available.

PMID:
21098468
41.

The biocompatibility of titanium cardiovascular devices seeded with autologous blood-derived endothelial progenitor cells: EPC-seeded antithrombotic Ti implants.

Achneck HE, Jamiolkowski RM, Jantzen AE, Haseltine JM, Lane WO, Huang JK, Galinat LJ, Serpe MJ, Lin FH, Li M, Parikh A, Ma L, Chen T, Sileshi B, Milano CA, Wallace CS, Stabler TV, Allen JD, Truskey GA, Lawson JH.

Biomaterials. 2011 Jan;32(1):10-8. doi: 10.1016/j.biomaterials.2010.08.073. Epub 2010 Nov 5.

42.

Application of energy-based technologies and topical hemostatic agents in the management of surgical hemostasis.

Sileshi B, Achneck H, Ma L, Lawson JH.

Vascular. 2010 Jul-Aug;18(4):197-204. Review.

PMID:
20643029
43.

Surgical aspects and biological considerations of arteriovenous fistula placement.

Achneck HE, Sileshi B, Li M, Partington EJ, Peterson DA, Lawson JH.

Semin Dial. 2010 Jan-Feb;23(1):25-33. doi: 10.1111/j.1525-139X.2009.00651.x. Review.

PMID:
20331815
44.

A comprehensive review of topical hemostatic agents: efficacy and recommendations for use.

Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH.

Ann Surg. 2010 Feb;251(2):217-28. doi: 10.1097/SLA.0b013e3181c3bcca. Review.

PMID:
20010084
45.

Multidisciplinary approach to the challenge of hemostasis.

Levy JH, Dutton RP, Hemphill JC 3rd, Shander A, Cooper D, Paidas MJ, Kessler CM, Holcomb JB, Lawson JH; Hemostasis Summit Participants.

Anesth Analg. 2010 Feb 1;110(2):354-64. doi: 10.1213/ANE.0b013e3181c84ba5. Epub 2009 Dec 10. Review.

PMID:
20007735
46.

Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study.

Conte MS, Nugent HM, Gaccione P, Guleria I, Roy-Chaudhury P, Lawson JH.

J Vasc Surg. 2009 Dec;50(6):1359-68.e1. doi: 10.1016/j.jvs.2009.07.108.

47.

Anticoagulation strategies for venous thromboembolism.

Peterson D, Harward S, Lawson JH.

Perspect Vasc Surg Endovasc Ther. 2009 Jun;21(2):125-32. doi: 10.1177/1531003509343018. Review.

PMID:
19767406
48.

Surgical excision of infected arteriovenous grafts: technique and review.

Ceppa EP, Sileshi B, Beasley GM, Lawson JH.

J Vasc Access. 2009 Jul-Sep;10(3):148-52. Review.

PMID:
19670165
49.

Regenerating titanium ventricular assist device surfaces after gold/palladium coating for scanning electron microscopy.

Achneck HE, Serpe MJ, Jamiolkowski RM, Eibest LM, Craig SL, Lawson JH.

Microsc Res Tech. 2010 Jan;73(1):71-6. doi: 10.1002/jemt.20757.

50.

Initial experience and outcome of a new hemodialysis access device for catheter-dependent patients.

Katzman HE, McLafferty RB, Ross JR, Glickman MH, Peden EK, Lawson JH.

J Vasc Surg. 2009 Sep;50(3):600-7, 607.e1. doi: 10.1016/j.jvs.2009.04.014. Epub 2009 Jul 22.

Supplemental Content

Loading ...
Support Center